Glioblastoma multiforme is a form of cancer with poor survival prognosis and few treatment options. The cerebrovascular barrier complicates the delivery of chemotherapeutic agents and contributes to poor treatment response in patients with this disease. Recently, dopamine D2 receptor antagonizing compounds, including the FDA-approved phenothiazine, thioridazine, were identified as potential anticancer therapeutics, but their mechanism of action is as yet poorly understood. We investigated the hypothesis that the cytotoxicity of thioridazine may be tied to disruption of lipid metabolism, specifically the synthesis of isoprenoids and cholesterol by the isoprenoid biosynthetic pathway. We show that, while pathway inhibitors lovastatin and zoledronate can sensitize U87MG and U251MG cells to thioridazine treatment, the addition of pathway intermediates cannot prevent thioridazine's cytotoxic effects. Treatment with methylschweinfurthin G, which is known to disrupt lipid trafficking, is able to sensitize these cell lines as well, suggesting that cholesterol availability or localization may be involved in these effects.
Introduction
Glioblastoma multiforme (GBM) is one of the most common central nervous system malignancies (Brodbelt et al., 2015; Alexander and Cloughesy, 2017; Ostrom et al., 2018) . While metastasis of GBM is rare, survival rates are dismal, with the vast majority of patients surviving under two years after diagnosis (Koshy et al., 2012; Brodbelt et al., 2015; Ostrom et al., 2018) .
The current standard of care, consisting of maximal surgical resection, radiotherapy, and chemotherapy with temozolomide (Alexander and Cloughesy, 2017) . While many types of cancer have benefited strongly from the development of targeted therapeutics, many of these have shown limited efficacy in GBM due to the exclusion of therapeutics by the blood-brain barrier (BBB) and the immune privilege of the environment (Maxwell et al., 2017; Touat et al., 2017) . Therapy is also complicated by inter-and intra-patient tumor heterogeneity (Sottoriva et al., 2013; Patel et al., 2014; Morokoff et al., 2015) and diffuse tumor margins (Chaichana et al., 2014; Pessina et al., 2017) . A novel treatment method using alternating electric fields has shown some efficacy, but no survival improvement over the current standard of care (Stupp et al., 2012) . To improve patient outcomes, new treatment options are needed.
Lipid modulation shows promise as an anti-GBM therapeutic target. Glial cancers like GBM are known to be highly dependent on lipid metabolism, cholesterol levels, and liver X receptor (LXR) function, suggesting lipid-targeting therapeutics, especially those which modulate cholesterol synthesis or trafficking, could have potential in the treatment of GBM (Villa et al., 2016) . Cholesterol is a product of the isoprenoid (or mevalonate) biosynthetic pathway (Figure 1 ), which may be pharmacologically inhibited by statins, such as lovastatin. Statins inhibit the rate limiting step of cholesterol synthesis catalyzed by HMGCoA reductase. Other enzymes within this pathway may also be modulated with chemical inhibitors, allowing the role of individual pathway intermediates in a given phenotype to be readily discerned by experimentation.
Recently, dopamine D2 receptor (D2R) antagonists have been identified as potential anticancer therapeutics (Rho et al., 2011; Sachlos et al., 2012; Yeh et al., 2012; Cheng et al., 2015; Huang et al., 2016) . In the case of GBM, their ability to pass through the blood-brain barrier makes them particularly attractive compounds (Batash et al., 2017; Touat et al., 2017; Harder et al., 2018) .
Numerous compounds of this class are approved by the Food and Drug Administration for treatment of mental illnesses, such as schizophrenia. A number of these D2R antagonists, especially those of the phenothiazine chemotype, have been shown to induce apoptosis (Gil-Ad et al., 2004) , decrease survival signaling (Park et al., 2014) , and reduce tumor size in xenograft models (Shin et al., 2013) . All of these effects are desirable in an anticancer therapeutic.
Interestingly, D2R antagonists are also known to disrupt lipid synthesis and trafficking (Masson et al., 1992) . It is not known if this dysregulation is required for their anticancer activity.
By the early 1990s, it was evident that cytotoxic concentrations of the phenothiazine D2R antagonist, chlorpromazine, inhibited sphingomyelinase activity and induced accumulation of unesterified cholesterol in large droplets within the cell (Masson et al., 1992) . Treatment with D2R
antagonists such as haloperidol and clozapine increased sterol responsive element binding protein 1/2 (SREBP) protein levels and induced upregulation of sterol-responsive genes such as HMGCR, APOE, ABCA1, LXR1/2, and others in the context of GaMg glioma cells (Ferno et al., 2006; VikMo et al., 2009) . This increase in mRNA may lead to a buildup of synthetic pathway intermediates, but appears to block cholesterol synthesis (Sanchez-Wandelmer et al., 2010; Canfran-Duque et al., 2013) .
Here, we more closely describe the role of the isoprenoid pathway in the mechanism of action for the phenothiazine D2R antagonist, thioridazine. Through a series of experiments involving supplementation with isoprenoid pathway intermediates and cotreatment with isoprenoid pathway inhibitors, we show that the anticancer efficacy of thioridazine is not reliant upon isoprenoid pathway disruption.
Methods

Cell culture and reagents
Cell lines U87MG and U251MG were purchased from American Type Culture Collection (ATCC, Manassas, VA). Both lines were cultured in MEM (Gibco, Waltham, MA) plus 10% FBS (HyClone, Logan, Utah) at 37ᵒC and 5% CO2. Cell lines were used within 20 passages of receipt.
Thioridazine (Sandoz Pharmaceuticals, Holzkirchen, Germany) was maintained as a 10 mM stock in dimethyl sulfoxide at -20ᵒC. Farnesol, geranylgeraniol, and mevalonate (1M stock) were obtained from Sigma Aldrich (St. Louis, MO). Lovastatin was activated as previously described (Dong et al., 2009) . DGBP was synthesized as previously described (Shull et al., 2006) and dissolved in water. Likewise, methyl schweinfurthin G was synthesized (Koubek et al., 2018) and protected from light at all times. All compound stocks were maintained at -20ᵒC at 10 mM in DMSO unless otherwise noted.
MTT assay
MTT assays were carried out as previously described (Weissenrieder et al., 2018) . Briefly, U87MG and U251MG cells were plated at 4000 cells/well in 96 well plates and allowed to seat overnight before treatment with 100 µL treatment media per well. Treatments were mixed in phenol red free MEM (Gibco, Waltham, MA) + 10% FBS. After 44 h of incubation at 37ᵒC and 5% CO2, 10 µL of 5 mg/mL MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Life Technologies, Waltham, MA) was added to each well. At 48 h, 100 µL of stop solution (10% 1 N HCl, 10% Triton X-100, 80% 2-propanol) was added and incubated at 37ᵒC overnight, then A570 (test) and A690 (reference) were read on a Spectramax i3x (Molecular Devices, Sunnyvale, CA). Absorbances were normalized to vehicle controls.
Statistics
All data is representative of 2-3 independent experiments in triplicate. Concentration response curves were generated via non-linear regression and compared with GraphPad Prism 8 (San Diego, CA). Flow cytometric data was analyzed via chi-square.
Results
Cotreatment with isoprenoid pathway inhibitor lovastatin sensitizes GBM cells to thioridazine treatment.
To observe if the cytotoxic effects of thioridazine were due to isoprenoid pathway alterations, we used 48 h MTT assays under concomitant treatment with pharmacological inhibitors of the pathway. For these experiments, we used 30 µM digeranyl bisphosphonate (DGBP), 10 µM zoledronate, and 3 µM activated lovastatin. At these concentrations, these compounds are known to selectively inhibit stages of the isoprenoid pathway ( Figure 1 ).
Lovastatin is a commonly used competitive inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the isoprenoid pathway. Treatment with lovastatin reduces substrate synthesis and availability for all future pathway enzymes, decreasing both cholesterol synthesis and isoprenoid pyrophosphate availability. Zoledronate, a bisphosphonate, acts downstream of lovastatin to reduce farnesyl pyrophosphate (FPP) synthesis and modulate downstream enzymes, such as farnesyl transferases and squalene synthase (Dunford et al., 2001 ). This represents a branch point in the isoprenoid pathway, where FPP may be used to isoprenylate proteins, synthesize geranylgeranyl pyrophosphate (GGPP), or begin the committed cholesterol biosynthetic process. Farnesyl transferases require the farnesyl pyrophosphate (FPP) substrate generated by the isoprenoid pathway to post-translationally modify, and thus regulate, small GTPases. These proteins, including Ras family members, are known to contribute to cancer development and metastasis. Squalene synthase, however, requires FPP for the first committed, rate-limiting step to synthesize cholesterol, itself a required component of cell membranes.
Downstream of FPP synthesis, DGBP selectively inhibits the synthesis of GGPP by geranylgeranyl diphosphate synthase (GGDPS), reducing the substrate availability for the isoprenylation of small GTPases in the Rho and Rab families by their respective transferases (geranylgeranyl transferase 1 and 2, respectively) (Wiemer et al., 2007; Wiemer et al., 2011) . This can disrupt cytoskeletal regulation, thus potentially contributing to dysregulation of metabolic processes and trafficking of required metabolic and structural substrates. These enzymes are later-stage enzymes in the isoprenoid pathway, subject to the regulation of upstream enzymes such as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR).
Metabolic activity of both U87MG and U251MG GBM cell lines were examined with 48 h MTT assays. We observed a small, yet statistically significant, reduction in inhibitory concentration (IC50) for thioridazine for cells cotreated with lovastatin and zoledronate (p<0.0001), but not for cells cotreated with DGBP (p>0.05) (Figure 2A-B) . This suggests that the isoprenoid biosynthetic pathway may be involved in the mechanism of action for thioridazine, since an inhibitor of this pathway is able to sensitize cells to thioridazine treatment. However, the disruption of small GTPase regulation by geranylgeranylation may not be involved in this process, indicating that the earlier steps in the biosynthetic pathway may be more critical for cell survival under treatment with thioridazine.
Exogenous supplementation of isoprenoid pathway intermediates does not protect GBM cells from thioridazine treatment.
Having observed that isoprenoid biosynthetic pathway inhibition could sensitize GBM cell lines to thioridazine treatment, we then examined whether the addition of pathway intermediates was sufficient to prevent the cytotoxic effects of thioridazine. This process is helpful to control for any non-selective effects of the pharmacological inhibitors in Figure 2 . For FPP and GGPP, we supplied the alcohols of these pyrophosphates, which are more chemically stable and membrane permeable than the highly charged pyophosphates. When we treated cells with thioridazine and 5 mM mevalonate, 30 µM farnesol, or 20 µM geranylgeraniol, we saw no significant increases in IC50 ( Figure 3A-B) . Indeed, supplementation with pathway intermediates farnesol and geranylgeraniol actually increased cytotoxicity (p<0.0001 for both). This may indicate that supplementation induced feedback inhibition on the isoprenoid pathway or that the protective effects of lovastatin and zoledronate are due to off-target interactions. However, the effects of mevalonate were more complex. Addback of mevalonate did not significantly sensitize U87MG cells to thioridazine, and it had a very slight, but statistically significant, protective effect on U251MG. This difference may be due to metabolic differences in the cell lines, but complicates findings.
Cotreatment with methyl-schweinfurthin G sensitizes cells to thioridazine treatment.
We also ascertained the effects of cotreatment with a novel anticancer therapeutic from the schweinfurthin family, methyl-schweinfurthin G (MeSG). These compounds are known to have potent anticancer effects in the sub-micromolar range in models of central nervous system malignancies such as GBM (Beutler et al., 1998) . While their anticancer mechanism of action is currently unknown, this class of compounds is known to disrupt lipid trafficking and metabolism in cell culture systems (Koubek et al., 2018) . When we cotreated U87MG and U251MG cells with 100 nM MeSG, we saw a half-log order shift suggesting a more robust sensitization of these cell lines to thioridazine ( Figure 4A-B) . This suggests that perhaps the localization and/or concentration of cholesterol, its metabolites, or its precursors may affect sensitivity of cell lines to thioridazine treatment.
Conclusions
Taken together, our results indicate that depletion of isoprenoid pathway intermediates via upstream inhibition may increase sensitivity of the GBM cell lines, U87MG and U251MG, to the anticancer activity of thioridazine. However, treatment with these intermediates added back to the media is not protective. This suggests that, while this pathway may be perturbed to sensitize cells, its products are not sufficient to protect GBM cells from the cytotoxic effects of thioridazine. Such findings may be rationalized in a number of ways. For one, a fully functional isoprenoid pathway may provide some protection against thioridazine, but low level function without the addition of pathway intermediates may be sufficient for this effect. In this paradigm, only profound, near-total blockade of the pathway is sufficient to have an effect. Another option is that such effects are dependent upon cholesterol concentration, and cholesterol is not Importantly, it is imperative to note that while the effects of isoprenoid biosynthetic pathway inhibitors are statistically significant, the magnitude of the effect is negligible in all experiments except perhaps for the experiments involving MeSG, where the curves are separated by half a log order. These findings may thus assist researchers in understanding the cytotoxic cascade initiated by thioridazine, but they likely have no direct translational applicability.
Current findings support a conclusion that thioridazine induces a metabolic crisis which may relate to lipid metabolism. However, these effects are not causative of cytotoxicity, but rather an effect of it. mM mevalonate had no effect on U87MG, but was slightly protective for U251MG (p<0.05). sensitized to thioridazine by 100 nM concentrations of the anticancer candidate compound, methyl-schweinfurthin G, which induced a half log order increase in sensitivity (p<0.0001).
